142 related articles for article (PubMed ID: 26954291)
1. Anti-human CD138 monoclonal antibodies and their bispecific formats: generation and characterization.
Chen D; Zou J; Zong Y; Meng H; An G; Yang L
Immunopharmacol Immunotoxicol; 2016 Jun; 38(3):175-83. PubMed ID: 26954291
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapy based on bispecific T-cell engager with hIgG1 Fc sequence as a new therapeutic strategy in multiple myeloma.
Zou J; Chen D; Zong Y; Ye S; Tang J; Meng H; An G; Zhang X; Yang L
Cancer Sci; 2015 May; 106(5):512-21. PubMed ID: 25664501
[TBL] [Abstract][Full Text] [Related]
3. Generating bispecific human IgG1 and IgG2 antibodies from any antibody pair.
Strop P; Ho WH; Boustany LM; Abdiche YN; Lindquist KC; Farias SE; Rickert M; Appah CT; Pascua E; Radcliffe T; Sutton J; Chaparro-Riggers J; Chen W; Casas MG; Chin SM; Wong OK; Liu SH; Vergara G; Shelton D; Rajpal A; Pons J
J Mol Biol; 2012 Jul; 420(3):204-19. PubMed ID: 22543237
[TBL] [Abstract][Full Text] [Related]
4. A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells.
Reusch U; Duell J; Ellwanger K; Herbrecht C; Knackmuss SH; Fucek I; Eser M; McAleese F; Molkenthin V; Gall FL; Topp M; Little M; Zhukovsky EA
MAbs; 2015; 7(3):584-604. PubMed ID: 25875246
[TBL] [Abstract][Full Text] [Related]
5. Rearranging the domain order of a diabody-based IgG-like bispecific antibody enhances its antitumor activity and improves its degradation resistance and pharmacokinetics.
Asano R; Shimomura I; Konno S; Ito A; Masakari Y; Orimo R; Taki S; Arai K; Ogata H; Okada M; Furumoto S; Onitsuka M; Omasa T; Hayashi H; Katayose Y; Unno M; Kudo T; Umetsu M; Kumagai I
MAbs; 2014; 6(5):1243-54. PubMed ID: 25517309
[TBL] [Abstract][Full Text] [Related]
6. Potent inhibition of local and disseminated tumor growth in immunocompetent mouse models by a bispecific antibody construct specific for Murine CD3.
Schlereth B; Kleindienst P; Fichtner I; Lorenczewski G; Brischwein K; Lippold S; da Silva A; Locher M; Kischel R; Lutterbüse R; Kufer P; Baeuerle PA
Cancer Immunol Immunother; 2006 Jul; 55(7):785-96. PubMed ID: 16187083
[TBL] [Abstract][Full Text] [Related]
7. A bispecific diabody directed against prostate-specific membrane antigen and CD3 induces T-cell mediated lysis of prostate cancer cells.
Bühler P; Wolf P; Gierschner D; Schaber I; Katzenwadel A; Schultze-Seemann W; Wetterauer U; Tacke M; Swamy M; Schamel WW; Elsässer-Beile U
Cancer Immunol Immunother; 2008 Jan; 57(1):43-52. PubMed ID: 17579857
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy with bispecific antibodies.
Thielemans KM
Verh K Acad Geneeskd Belg; 1995; 57(3):229-47; discussion 247-8. PubMed ID: 7483816
[TBL] [Abstract][Full Text] [Related]
9. Engineering a CD123xCD3 bispecific scFv immunofusion for the treatment of leukemia and elimination of leukemia stem cells.
Kuo SR; Wong L; Liu JS
Protein Eng Des Sel; 2012 Oct; 25(10):561-9. PubMed ID: 22740616
[TBL] [Abstract][Full Text] [Related]
10. Unexpected recombinations in single chain bispecific anti-CD3-anti-CD33 antibodies can be avoided by a novel linker module.
Stamova S; Cartellieri M; Feldmann A; Arndt C; Koristka S; Bartsch H; Bippes CC; Wehner R; Schmitz M; von Bonin M; Bornhäuser M; Ehninger G; Bachmann M
Mol Immunol; 2011 Dec; 49(3):474-82. PubMed ID: 22014687
[TBL] [Abstract][Full Text] [Related]
11. Carcinoembryonic antigen (CEA)-specific T-cell activation in colon carcinoma induced by anti-CD3 x anti-CEA bispecific diabodies and B7 x anti-CEA bispecific fusion proteins.
Holliger P; Manzke O; Span M; Hawkins R; Fleischmann B; Qinghua L; Wolf J; Diehl V; Cochet O; Winter G; Bohlen H
Cancer Res; 1999 Jun; 59(12):2909-16. PubMed ID: 10383154
[TBL] [Abstract][Full Text] [Related]
12. Bispecific Antibody Armed T Cells to Target Cancer Cells.
Thakur A; Lum LG; Mittal S
Methods Mol Biol; 2018; 1722():117-126. PubMed ID: 29264802
[TBL] [Abstract][Full Text] [Related]
13. CD19-/CD3-bispecific antibody of the BiTE class is far superior to tandem diabody with respect to redirected tumor cell lysis.
Mølhøj M; Crommer S; Brischwein K; Rau D; Sriskandarajah M; Hoffmann P; Kufer P; Hofmeister R; Baeuerle PA
Mol Immunol; 2007 Mar; 44(8):1935-43. PubMed ID: 17083975
[TBL] [Abstract][Full Text] [Related]
14. A novel recombinant bispecific single-chain antibody, bscWue-1 x CD3, induces T-cell-mediated cytotoxicity towards human multiple myeloma cells.
Hönemann D; Kufer P; Rimpler MM; Chatterjee M; Friedl S; Riecher F; Bommert K; Dörken B; Bargou RC
Leukemia; 2004 Mar; 18(3):636-44. PubMed ID: 14737072
[TBL] [Abstract][Full Text] [Related]
15. Cytolysis of leukemic B-cells by T-cells activated via two bispecific antibodies.
Bohlen H; Manzke O; Patel B; Moldenhauer G; Dörken B; von Fliedner V; Diehl V; Tesch H
Cancer Res; 1993 Sep; 53(18):4310-4. PubMed ID: 7689932
[TBL] [Abstract][Full Text] [Related]
16. Treatment of murine B cell lymphoma with bispecific monoclonal antibodies (anti-idiotype x anti-CD3).
Demanet C; Brissinck J; Van Mechelen M; Leo O; Thielemans K
J Immunol; 1991 Aug; 147(3):1091-7. PubMed ID: 1830596
[TBL] [Abstract][Full Text] [Related]
17. Biologic properties of a bispecific single-chain antibody directed against 17-1A (EpCAM) and CD3: tumor cell-dependent T cell stimulation and cytotoxic activity.
Mack M; Gruber R; Schmidt S; Riethmüller G; Kufer P
J Immunol; 1997 Apr; 158(8):3965-70. PubMed ID: 9103467
[TBL] [Abstract][Full Text] [Related]
18. In vivo studies using bispecific antibodies (anti-CD3 x anti-idiotype) and CD28-induced costimulation in the BCL1 lymphoma.
Demanet C; Brissinck J; De Jonge J; Thielemans K
J Hematother; 1995 Oct; 4(5):363-8. PubMed ID: 8581370
[TBL] [Abstract][Full Text] [Related]
19. Retargeting T cells to GD2 pentasaccharide on human tumors using Bispecific humanized antibody.
Xu H; Cheng M; Guo H; Chen Y; Huse M; Cheung NK
Cancer Immunol Res; 2015 Mar; 3(3):266-77. PubMed ID: 25542634
[TBL] [Abstract][Full Text] [Related]
20. Activation of resting T cells against the CA 72-4 tumor antigen with an anti-CD3/CA 72-4 bispecific antibody in combination with a costimulatory anti-CD28 antibody.
Hombach A; Mathas S; Jensen M; Tillmann T; Menges M; Diehl V; Kruis W; Pohl C
Anticancer Res; 1997; 17(3C):2025-32. PubMed ID: 9216660
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]